Focused On-demand Library for Nuclease EXOG, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y2C4

UPID:

EXOG_HUMAN

Alternative names:

Endonuclease G-like 1

Alternative UPACC:

Q9Y2C4; A8K242; B4DVG2; Q3SXM9; Q9Y2C8

Background:

Nuclease EXOG, mitochondrial, also known as Endonuclease G-like 1, plays a crucial role in cellular processes with its endo/exonuclease activities. It exhibits a preference for single-stranded DNA and demonstrates significant nicking activity towards supercoiled DNA, alongside 5'-3' exonuclease activity. This protein's unique ability to interact with DNA makes it a key player in mitochondrial DNA maintenance and repair.

Therapeutic significance:

Understanding the role of Nuclease EXOG, mitochondrial could open doors to potential therapeutic strategies. Its involvement in DNA repair mechanisms positions it as a potential target for interventions in diseases where DNA damage is a contributing factor.